Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
2.
Front Oncol ; 11: 771749, 2021.
Article in English | MEDLINE | ID: mdl-34760708

ABSTRACT

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is one of the most fatal cancers in the world. The 5-year survival rate of ESCC is <30%. However, few biomarkers can accurately predict the prognosis of patients with ESCC. We aimed to identify potential survival-associated biomarkers for ESCC to improve its poor prognosis. METHODS: ImmuneAI analysis was first used to access the immune cell abundance of ESCC. Then, ESTIMATE analysis was performed to explore the tumor microenvironment (TME), and differential analysis was used for the selection of immune-related differentially expressed genes (DEGs). Weighted gene coexpression network analysis (WGCNA) was used for selecting the candidate DEGs. Least absolute shrinkage and selection operator (LASSO) Cox regression was used to build the immune-cell-associated prognostic model (ICPM). Kaplan-Meier curve of survival analysis was performed to evaluate the efficacy of the ICPM. RESULTS: Based on the ESTIMATE and ImmuneAI analysis, we obtained 24 immune cells' abundance. Next, we identified six coexpression module that was associated with the abundance. Then, LASSO regression models were constructed by selecting the genes in the module that is most relevant to immune cells. Two test dataset was used to testify the model, and we finally, obtained a seven-genes survival model that performed an excellent prognostic efficacy. CONCLUSION: In the current study, we filtered seven key genes that may be potential prognostic biomarkers of ESCC, and they may be used as new factors to improve the prognosis of cancer.

3.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 29(2): 615-619, 2021 Apr.
Article in Chinese | MEDLINE | ID: mdl-33812440

ABSTRACT

OBJECTIVE: To compare the plasma components of frozen plasma (FP) and fresh frozen plasma (FFP). METHODS: Twenty samples of FP and 20 samples of FFP from Beijing Red Cross Blood Center were randomly selected. Immediately after plasma melting, 12 plasma components including coagulation factor, fibrinolytic system and anticoagulation protein were detected, including activated partial thromboplastin time (APTT), prothrombin time (PT), coagulation factor Ⅷ (FⅧ) activity, coagulation factor Ⅴ (FⅤ) activity, fibrinogen(FIB) level, ADAMTS-13 activity, von Willebrand factor(vWF) activity, D-dimer (D-dimer, DD), fibrin degradation products (FDP), antithrombin (AT), protein C (PC), and protein S (PS). All these coagulation components between the two types of plasma were compared and analyzed. RESULTS: Compared with FFP, APTT in FP was significantly prolonged(t=3.428, P<0.01), and PT was also significantly prolonged(z=-2.140, P<0.05), and FⅧ activity was decreased (t=-3.372, P<0.01), but all in the reference range, and PS activity was decreased(t=-2.458,P<0.05), there was no statistical difference in the other part between two types of plasma(P>0.05). CONCLUSION: FP can substitute FFP in the treatment of some diseases, although it is lack of some coagulation factors and anticoagulation protein.


Subject(s)
Blood Coagulation Factors , Plasma , Beijing , Blood Coagulation , Blood Coagulation Tests , Humans
4.
Biol Sex Differ ; 11(1): 58, 2020 10 22.
Article in English | MEDLINE | ID: mdl-33092635

ABSTRACT

BACKGROUND: Asparagine and aspartate homeostasis are linked with type 2 diabetes (T2D). This study aimed to explore whether asparagine and aspartate metabolism interacted with sex and age to increase the risk of T2D. METHODS: From 27 May 2015 to 3 August 2016, we consecutively retrieved 1032 T2D patients and 1522 subjects without T2D from a tertiary care hospital in Liaoning, China. Restricted cubic spline nested in the logistic regression was used to draw odds ratio curves of plasma asparagine to aspartate ratio for T2D by sex and age. Cut-off point was selected where curves went apart, indicating possible interaction. Addictive interactions of asparagine to aspartate ratio with sex or age and secondary interaction with copresence of unfavorable sex and age were further estimated using relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S). RESULTS: Ratio of asparagine to aspartate > 1.5 was associated with elevated risk of T2D (OR 7.99, 95%CI 5.50 to 11.6), which was enhanced by female gender to 13.6, (95%CI 8.10-22.9) and by > 50 years of age to 28.7 (14.6-56.3), with significant additive interactions. There was a significant secondary-interaction of copresence of female sex and > 50 years of age with high asparagine to aspartate ratio for increased T2D risk with the OR being further increased to 34.4 (20.5-57.5). CONCLUSIONS: High asparagine to aspartate ratio was associated with markedly increased risk of T2D, which was further amplified by either female gender or > 50 years of age, and especially both.


Subject(s)
Aging , Asparagine/metabolism , Aspartic Acid/metabolism , Diabetes Mellitus, Type 2/metabolism , Homeostasis/physiology , Adolescent , Adult , Asian People , China , Diabetes Mellitus, Type 2/genetics , Female , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors , Sex Factors , Young Adult
5.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 28(3): 961-966, 2020 Jun.
Article in Chinese | MEDLINE | ID: mdl-32552965

ABSTRACT

OBJECTIVE: To retrospectively analyze the identification results of irregular antibodies, to clarify the distribution features and to explore the relation of alloantibodies and autoantibodies with the immunized history of patients and disease kinds. METHODS: 49 820 patients who applied for red blood transfusion during Sep 1st 2017 to Sep 1st 2018 were selected. All the specimens were screened for the antibody by microcolumn gel antiglobulin technique, which then were identified for irregular antibody. RESULTS: Antibodies were found in 861 (1.73%) of all 49 820 transfused samples. The alloimmunization history of the patients with antibodies was significantly different between male and female (χ2=18.54,P<0.01). The alloantibody was the most common, accounting for 59.50% in all of the antibodies. Warm autoantibody, anti-E, anti-M, anti-cE and anti-Ce accounted for 68.5% of the antibodies. The blood group of Rh, MNS and Lewis were responsible for 92.40% of alloantibody, especially anti-E accounted for the largest percentage(38.60%) of alloantibody. Patients with alloantiboies experienced much more the alloimmunization and transfusion history (χ2=20.13,P<0.01;χ2=5.40,P<0.05) . The distribution of auto and alloantibody was very significantly different among the ddifferent isease (χ2=51.8,P<0.01), Hematopathy, solid tumor and osteoarthropathy were often associated with alloantibody, otherwise, autoantibodies often occurred in hematopathy and autoimmune disease. CONCLUSION: The most important factor that results in antibody-screening positive is alloantibody, in which anti-E antibody from Rh blood group system in most common.


Subject(s)
Antibodies/immunology , Erythrocytes , Blood Group Antigens , Blood Transfusion , Female , Humans , Isoantibodies , Male , Retrospective Studies
6.
J Cell Mol Med ; 24(13): 7504-7514, 2020 07.
Article in English | MEDLINE | ID: mdl-32412186

ABSTRACT

Despite the prognostic value of IDH and other gene mutations found in diffuse glioma, markers that judge individual prognosis of patients with diffuse lower-grade glioma (LGG) are still lacking. This study aims to develop an expression-based microRNA signature to provide survival and radiotherapeutic response prediction for LGG patients. MicroRNA expression profiles and relevant clinical information of LGG patients were downloaded from The Cancer Genome Atlas (TCGA; the training group) and the Chinese Glioma Genome Atlas (CGGA; the test group). Cox regression analysis, random survival forests-variable hunting (RSFVH) screening and receiver operating characteristic (ROC) were used to identify the prognostic microRNA signature. ROC and TimeROC curves were plotted to compare the predictive ability of IDH mutation and the signature. Stratification analysis was conducted in patients with radiotherapy information. Gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed to explore the biological function of the signature. We identified a five-microRNA signature that can classify patients into low-risk or high-risk group with significantly different survival in the training and test datasets (P < 0.001). The five-microRNA signature was proved to be superior to IDH mutation in survival prediction (AUCtraining = 0.688 vs 0.607). Stratification analysis found the signature could further divide patients after radiotherapy into two risk groups. GO and KEGG analyses revealed that microRNAs from the prognostic signature were mainly enriched in cancer-associated pathways. The newly discovered five-microRNA signature could predict survival and radiotherapeutic response of LGG patients based on individual microRNA expression.


Subject(s)
Brain Neoplasms/genetics , Brain Neoplasms/radiotherapy , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Glioma/genetics , Glioma/radiotherapy , MicroRNAs/genetics , Adult , Brain Neoplasms/pathology , Databases, Genetic , Female , Glioma/pathology , Humans , Isocitrate Dehydrogenase/genetics , Kaplan-Meier Estimate , Male , MicroRNAs/metabolism , Middle Aged , Multivariate Analysis , Mutation/genetics , Neoplasm Grading , Prognosis , Proportional Hazards Models , Survival Analysis
7.
J Leukoc Biol ; 108(6): 1765-1776, 2020 12.
Article in English | MEDLINE | ID: mdl-32421907

ABSTRACT

Extracellular vesicles (EVs) are small, double-membrane vesicles derived from erythrocytes, leukocytes, platelets, and cells of multiple tissues under physiologic or pathologic conditions. The role of EVs in stored RBC units is of great interest with respect to transfusion-related immunomodulation. The current study focuses on the quantity of EVs isolated from stored RBC units and their action on B cell-mediated immune responses. The in vitro experiment demonstrated that EVs exhibited a negative role in B cell survival, plasmacytic differentiation, and class switch recombination under LPS stimulation. Furthermore, LPS-induced antibody production was significantly decreased after EVs injection in vivo. Biochemical analysis revealed that EVs hampered the expression of Blimp-1 and IRF4 and the activation of NF-κB pathway in LPS-primed B cells. Overall, these data imply a vital role for EVs isolated from RBC units in B cell-mediated immune responses.


Subject(s)
Blood Preservation , Cell Differentiation/immunology , Erythrocytes/immunology , Extracellular Vesicles/immunology , Plasma Cells/immunology , Animals , Cell Differentiation/drug effects , Interferon Regulatory Factors/immunology , Lipopolysaccharides/pharmacology , Mice , Mice, Inbred NOD , Mice, SCID , Positive Regulatory Domain I-Binding Factor 1/immunology
8.
J Clin Apher ; 35(3): 154-162, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32110837

ABSTRACT

INTRODUCTION: Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening thrombotic microangiopathy. Therapeutic plasma exchange (TPE) is the first-line treatment for TTP. In our institution, albumin plus plasma (fresh frozen plasma [FFP] and/or cryoprecipitate-reduced plasma [CRP]) has been used as replacement fluid since 2014. We aimed to evaluate the efficacy of albumin combined with plasma as TPE for TTP. MATERIAL AND METHODS: We retrospectively evaluated 20 patients admitted to our institution due to an acute episode of TTP between January 1, 2014 and February 1, 2019. They were divided into two groups according to the replacement fluid protocols: (a) albumin plus FFP (1:1) and (b) albumin plus mixed plasma [ie, albumin and FFP with CRP (2:1:1)] groups. Data on patient characteristics, replacement parameters, outcome, and hemorrhage risk were collected and analyzed. RESULTS: There were no significant differences in treatment outcomes between the two groups (P > .05). However, the albumin plus mixed plasma group tended to require fewer plasma exchanges (median, 4) and shorter time to response (median, 15 days) compared to albumin plus FFP group (median, 6; 31 days). Although the cumulative survival of the albumin plus mixed plasma group was higher than the other group starting from day 23 after treatment, we did not observe significant difference (P = .50). No significant increase in the risk for hemorrhage was observed in either group. CONCLUSIONS: The therapeutic efficacy of albumin and mixed plasma (2:1:1) is not inferior to that of albumin and FFP (1:1), and it can be used in treating TTP.


Subject(s)
Albumins/therapeutic use , Plasma Exchange/methods , Plasma/metabolism , Purpura, Thrombotic Thrombocytopenic/therapy , Adult , Aged , Blood Component Removal/methods , Female , Hemorrhage/prevention & control , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Risk , Treatment Outcome
9.
Front Endocrinol (Lausanne) ; 11: 619422, 2020.
Article in English | MEDLINE | ID: mdl-33633688

ABSTRACT

Objective: This study aimed to evaluate how leucine are associated with diabetic nephropathy (DN) in type 2 diabetes (T2D) patients and the gender difference of this association. Methods: We retrieved 1,031 consecutive patients with T2D who meet the inclusion and exclusion criteria from the same tertiary care center and extracted clinical information from electronic medical record. Plasma leucine was measured by liquid chromatography-mass spectrometer. Restricted cubic spline (RCS) was conducted to examine potential non-linear relationship between leucine and the risk of DN. Logistic regression was used to obtain odds ratio (OR) and confidence interval (CI). Additive interaction was used to estimate the interaction effect between leucine and gender for DN. Results: We found there was a negative correlation between leucine and the risk of DN. After stratifying all patients by gender, this relationship only remained significant in women (OR:0.57, CI:0.41-0.79). Conclusions: In conclusion, T2D patients with high levels of leucine have a lower risk of developing DN in female.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/epidemiology , Diabetic Nephropathies/blood , Diabetic Nephropathies/epidemiology , Leucine/blood , Sex Characteristics , Adult , Aged , Biomarkers/blood , China/epidemiology , Cross-Sectional Studies , Diabetes Mellitus, Type 2/diagnosis , Diabetic Nephropathies/diagnosis , Female , Humans , Male , Middle Aged , Risk Factors
10.
Sci Rep ; 9(1): 19767, 2019 12 24.
Article in English | MEDLINE | ID: mdl-31875006

ABSTRACT

Autoimmune hemolytic anemia (AIHA) is an acquired autoimmune disease mediated by antibodies against the patient's red blood cells. However, the underlying mechanisms for antibody production are not fully understood. Previous studies of etiology and pathogenesis of AIHA mainly focus on autoreactive B cells that have escaped tolerance mechanisms. Few studies have reported the function of TFH and TFR cells in the process of AIHA. The present study aimed to explore the potential mechanism of TFH and TFR cells in the pathogenesis of AIHA. With the model of murine AIHA, increased ratios of TFH:TFR, elevated serum IL-21 and IL-6 levels, and upregulated Bcl-6 and c-Maf expression were reported. Also, adoptive transfer of purified CD4+CXCR5+CD25- T cells from immunized mice promoted the induction of autoantibody in the AIHA mouse model. Altogether, our data demonstrate the important role of TFH cells for control and induction of AIHA. In the light of the key contributions of TFH cells to the immune response in AIHA, strategies aimed at inhibiting the TFH development or function should be emphasized.


Subject(s)
Anemia, Hemolytic, Autoimmune/immunology , B-Lymphocytes/immunology , Germinal Center/immunology , T-Lymphocytes, Regulatory/immunology , Anemia, Hemolytic, Autoimmune/pathology , Animals , Autoantibodies/immunology , Disease Models, Animal , Germinal Center/pathology , Interleukin-6/immunology , Interleukins/immunology , Mice , Proto-Oncogene Proteins c-bcl-6/immunology , Proto-Oncogene Proteins c-maf/immunology , T-Lymphocytes, Regulatory/pathology
11.
Clin Lab ; 63(4): 765-771, 2017 Apr 01.
Article in English | MEDLINE | ID: mdl-28397467

ABSTRACT

BACKGROUND: Complement activation is critically involved in multiple autoimmune diseases. Immune thrombocytopenia (ITP) is a hemorrhagic condition with enhanced platelet clearance caused by antiplatelet autoantibodies. However, the roles of complements C3a, C5a, and soluble C5b-9 (sC5b-9) in the hemorrhage of ITP remain unknown. METHODS: Plasma C3a, C5a, and sC5b-9 levels in ITP patients were measured by enzyme-linked immunosorbent assay (ELISA). Antiplatelet autoantibodies (anti-GPIIb/IIIa and anti-GPIbα) were evaluated by modified monoclonal antibody immobilization of platelet antigen (MAIPA) assay. The severity of bleeding was assessed using the validated bleeding score for each ITP patient at onset. RESULTS: Levels of C3a, C5a, and sC5b-9 were significantly increased in active ITP patients, compared with those in controls (p < 0.001). However, levels of C3a, C5a, and sC5b-9 were not changed by treatment of HD-DXM. In addition, the C3a levels were correlated with the increase in bleeding scores from the patients with ITP (p < 0.05, r = 0.256). In contrast, neither platelet counts nor antiplatelet autoantibodies (anti-GPIIb/IIIa and anti-GPIbα) showed any correlation with levels of C3a, C5a, and sC5b-9. CONCLUSIONS: Levels of C3a, C5a, and sC5b-9 are increased in patients with ITP, suggesting a hyperactive complement system. Certain complement components, such as C3a, may contribute to hemorrhage of patients with ITP.


Subject(s)
Purpura, Thrombocytopenic, Idiopathic , Autoantibodies , Blood Platelets , Complement C3a , Enzyme-Linked Immunosorbent Assay , Humans , Platelet Count
12.
J Pediatr Hematol Oncol ; 36(8): 617-23, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25072364

ABSTRACT

Bone marrow-derived mesenchymal stem cells (BM-MSCs) in the marrow stroma provide a scaffold for hematopoiesis. Chemokine stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4 have been shown to affect the engraftment of hematopoietic stem cells. However, little is known about SDF-1/CXCR4's functions in regulating BM-MSCs in humans. As an initial step toward this issue, we have evaluated expression of SDF-1/CXCR4 in the BM-MSCs from a cohort of adolescents and young adults with acute lymphoblastic leukemia (ALL). We found a decrease of the CXCR4 level and an increase of the SDF-1 level in these MSCs of ALL. Moreover, cell migration appeared to be impaired in the MSCs of ALL. These changes were reversed by chemotherapy. Taken together, alteration of SDF-1/CXCR4 expression could be potentially developed as biomarkers for monitoring the effectiveness of chemotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Chemokine CXCL12/genetics , Drug Monitoring/methods , Mesenchymal Stem Cells/drug effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Receptors, CXCR4/genetics , Adolescent , Bone Marrow Cells/drug effects , Bone Marrow Cells/physiology , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cell Movement/drug effects , Cell Movement/physiology , Cells, Cultured , Chemokine CXCL12/metabolism , Dipeptidyl Peptidase 4/genetics , Dipeptidyl Peptidase 4/metabolism , Gene Expression/drug effects , Hematopoiesis/drug effects , Hematopoiesis/physiology , Humans , Mesenchymal Stem Cells/physiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Receptors, CXCR4/metabolism , Young Adult
13.
Chin Med J (Engl) ; 126(22): 4254-9, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24238507

ABSTRACT

BACKGROUND: In bone marrow transplant patients, the microenvironment in bone marrow is damaged after chemotherapy or radiotherapy. Subsequent to allogenic hematopoietic stem cell transplantation in patients with clinically successful engraftments, the source of mesenchymal stem cells (MSCs) remains controversial. To further verify the stimulatory effect of the simultaneous transplantation of cells from second donors on engraftment success for hematopoietic stem cell transplantation in support of donor MSCs engraftments, the aim of this study is to monitor the dynamics of the engraftment of bone marrow-derived MSCs in patients after transplantation with mismatched-sex hematopoietic stem and third-party cells. METHODS: In this study, the hematopoietic stem cells from 32 clinical donors of different sexes that resulted in successful engraftments were selected for transplantation and were classified into three groups for research purposes: group A consisted of 14 cases of transplantation with bone marrow and recruited peripheral hematopoietic stem cell transplantation, group B contained 8 cases of simultaneous re-transfusion of MSCs from the second donor, and group C contained 10 cases of simultaneous re-transfusion of umbilical blood from the second donor. The bone marrow from 32 patients with successful engraftments of hematopoietic transplantation were selected and sub-cultured with MSCs. Flow cytometry (FCM) was used to measure the expression of surface antigens on MSCs. Denaturing high-performance liquid chromatography (DHPLC) in combination with polymerase chain reaction amplification of short tandem repeats (STRPCR) was used to measure the engraftment status of fifth-generation MSCs in patients. Fluorescence in situ hybridization (FISH) revealed the sex origin of the fifth-generation MSCs in 32 patients. Dynamic examinations were performed on patients receiving donor transplantations. RESULTS: The progenies of fifth-generation MSCs were successfully cultured in 32 cases. The results of FCM demonstrated that the expression levels of CD14+ and CD45+ cells were lower than 0.04% in the fifth-generation MSCs. The analysis using DHPLC and FISH showed similar results. One patient from group B also received a temporary transplantation of MSCs from the donor. The MSCs in the remaining 31 patients all originated from the patients themselves. CONCLUSIONS: After transplantation, the MSCs present in patients originated from the host. In patients transplanted with MSCs from a second donor, the phenomenon of temporary chimerization of MSCs was observed.


Subject(s)
Hematopoietic Stem Cell Transplantation , Mesenchymal Stem Cells/cytology , Adolescent , Adult , Cells, Cultured , Chromatography, High Pressure Liquid , Female , Flow Cytometry , Humans , Leukocyte Common Antigens/metabolism , Lipopolysaccharide Receptors/metabolism , Male , Mesenchymal Stem Cells/metabolism , Middle Aged , Young Adult
14.
Int J Hematol ; 93(6): 750-759, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21607655

ABSTRACT

Chemokine stromal-derived factor-1 (SDF-1) and its receptor CXCR4 have been shown to play an important role in the migration and homing of the transplanted hematopoietic stem cells (HSCs). Mesenchymal stem cells (MSCs) express these molecules. This study is to test the hypothesis that acute myeloid leukemia (AML) alters the expression of SDF-1/CXCR4 in human bone marrow MSCs. Expression of both CXCR4 and SDF-1 was found to be increased, but excessively retained, in the MSCs in AML. In contrast, the SDF-1 level in bone marrow plasma and supernatant of cultured MSCs from AML patients were reduced, while the SDF-1 was able to efficiently induce a dose-dependent migration of MSCs in vitro. Our results demonstrate that altered expression and distribution of SDF-1/CXCR4 in MSCs may contribute to SDF-1 deficiency in the plasma of AML patients. The migration of MSCs may be negatively affected by the SDF-1 deficiency.


Subject(s)
Bone Marrow/physiopathology , Chemokine CXCL12/deficiency , Chemokine CXCL12/metabolism , Gene Expression Regulation, Leukemic , Leukemia, Myeloid, Acute/physiopathology , Receptors, CXCR4/metabolism , Adolescent , Adult , Cell Movement , Chemokine CXCL12/genetics , Female , Hematopoietic Stem Cell Transplantation , Humans , Intracellular Space/metabolism , Leukemia, Myeloid, Acute/genetics , Male , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Middle Aged , Receptors, CXCR4/genetics , Signal Transduction , Young Adult
15.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 18(1): 155-60, 2010 Feb.
Article in Chinese | MEDLINE | ID: mdl-20137138

ABSTRACT

The aim of this study was to investigate the role of mesenchymal stem cells in the hematopoietic reconstitution of patients who had received haploidentical allogeneic hematopoietic stem cell transplantation (hi-allo-HSCT). 15 patients who underwent treatment with both MSCs and HSCs, were selected as study group, while 20 patients receiving only HSCT were taken as control. Bone marrow samples were obtained from iliac crest aspirates at several times after HSCT for the isolation, purification and expansion of MSCs. The confluent ratio and time were measured and compared with those of the control. The peripheral blood samples were obtained from patients, then absolute neutrophil and platelet counts were assayed. From day 4 before transplantation to day 28 after transplantation, serum was obtained every four days from patients of the two groups, and then 3 cytokines as SDF-1alpha, TPO and IL-11 were detected by ELISA. The results indicated that as compared with the control group, the ratio of primary confluent layer formation of MSCs in study group was obviously higher (27.3%) (p < 0.01), and the confluence time in culture was significantly less (p < 0.05). In the study group, the concentration of SDF-1alpha amounted to peak value (2975.19 +/- 681.56 pg/ml) on the 8th day after HSCT, which was obviously higher than that before HSCT (2403.70 +/- 522.39 pg/ml, p < 0.05), whereas in the control, the concentration of highest point of SDF-1alpha reached to peak valve (2280.60 +/- 701.25 pg/ml) on the 16th day after HSCT, which was less than that before HSCT (2701.46 +/- 483.21 pg/ml, p < 0.05). The concentration of TPO and IL-11 was higher in study group compared with the control from day 16 to 28 after HSCT (p < 0.05). It is concluded that the transfusion of MSCs combined with hi-all-HSCT may improve the injured state of the hematopoietic microenvironment in bone marrow of patients during allo-HSCT.


Subject(s)
Bone Marrow/metabolism , Hematopoietic Stem Cell Transplantation/methods , Mesenchymal Stem Cell Transplantation/methods , Adolescent , Adult , Bone Marrow/pathology , Chemokine CXCL12/metabolism , Child , Hematopoietic System , Humans , Interleukin-11/metabolism , Middle Aged , Thrombopoietin/metabolism , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...